Alkermes to Host Conference Call to Discuss Financial Results for First Quarter of Fiscal 2011

WALTHAM, Mass.--(BUSINESS WIRE)-- Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m. ET on Thursday, August 5, 2010, to discuss the company’s financial results for the first quarter of fiscal 2011. Management will review the quarter and provide an update on the company.

The conference call will be webcast on the investor relations section of Alkermes’ website at www.alkermes.com or may be accessed by dialing 1-888-424-8151 for domestic callers and 1-847-585-4422 for international callers. The conference call ID number is 6037988.

A replay of the conference call will be available from 7:30 p.m. ET on Thursday, August 5, 2010, through 5:00 p.m. ET on Thursday, August 12, 2010, and may be accessed by visiting Alkermes’ website or by dialing 1-888-843-8996 for domestic callers and 1-630-652-3044 for international callers. The replay access code is 6037988.

About Alkermes

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Massachusetts, Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.



CONTACT:

Alkermes, Inc.
Eva Stroynowski, 781-609-6823
Corporate Communications

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Mental Health  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.